Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 28Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Cyclophosphamide 414Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 69Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × orelabrutinib × Other hematologic neoplasm × Clear all
NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
79 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05322733 2022-04-19

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡